Microbicides
Microbicides
AAPS Showcases Vaginal Ring with Tenofovir + Contraceptive, Gel Suitable for Vaginal and Rectal Use
- Details
- Category: HIV Prevention
- Published on Friday, 15 November 2013 00:00
- Written by Liz Highleyman
A new intravaginal ring delivers both tenofovir for HIV prevention and levonorgestrel for contraception for 3 months, researchers reported at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition taking place this week in San Antonio. Other studies looked at a novel gel for both vaginal and rectal use containing the antiretroviral IQP-0528, and a bio-adhesive vaginal gel combining tenofovir and the anti-herpes drug acyclovir.
ICAAC 2013: Tenofovir Vaginal Ring Protects Monkeys on Depo-Provera Against HIV-like Virus
- Details
- Category: HIV Prevention
- Published on Tuesday, 24 September 2013 00:00
- Written by Liz Highleyman
An intravaginal ring containing tenofovir protected all but 1 macaque monkey given hormonal contraceptives and repeatedly exposed to a hybrid human/simian virus similar to HIV, according to a late-breaker presentation at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013) this month in Denver.
Lubricants for Sex Can Damage Cells, but Did Not Increase HIV Risk in Lab Study
- Details
- Category: HIV Prevention
- Published on Tuesday, 11 December 2012 00:00
- Written by Liz Highleyman
Certain sexual lubricant formulations are toxic to cells and can cause damage to the epithelial lining of the vagina or rectum, but this did not appear to facilitate HIV infection, researchers reported in the November 7, 2012, edition of the open-access journal PLoS ONE. 
Reformulated Tenofovir Gel Found Safe and Acceptable for Anal Sex
- Details
- Category: HIV Prevention
- Published on Friday, 26 April 2013 00:00
- Written by Microbicide Trials Network
Men and women found a microbicide gel containing 1% tenofovir -- which has been shown to reduce the risk of HIV infection during vaginal sex -- to also be acceptable for anal use after it was reformulated to reduce the amount of an ingredient that led to irritation in an earlier study, according to a report in the April 3, 2013, edition of PLoS ONE.
Immune Activation Raised HIV Risk in CAPRISA Trial, but Some Develop Protective Antibodies
- Details
- Category: HIV Prevention
- Published on Tuesday, 06 November 2012 00:00
- Written by Liz Highleyman
Women in the CAPRISA 004 vaginal gel trial who showed evidence of prior immune activation had an increased likelihood of becoming infected with HIV, researchers recently reported. Another CAPRISA analysis found that 2 women exhibitedbroadly cross-neutralizing antibodies targeting a newly emergent antigen on HIV's envelope -- a discovery that could advance vaccine research.
Web Design and Development by